Analyst Brief July 20, 2026

H.R. 8205 — Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, as amended

Current Status

Reported with an amendment, committed to the Committee of the Whole House

Executive Summary

H.R. 8205 reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031, preventing a lapse in critical research and grant programs set to expire in 2026. Beyond a simple extension, the bill tightens oversight by requiring the HHS Secretary to assess efficacy and safety data during grant renewals and mandating that researchers promptly report serious adverse events in phase 3 trials. It also forces the FDA to maintain long-term strategic focus by requiring the publication of a 5-year 'FDA Rare Neurodegenerative Disease Action Plan' within 18 months of enactment.

Bill Data

Primary Sponsor

Rep. Mike Quigley (D-IL)

Bill Number

H.R. 8205

Session

119th

Co-Sponsors

Rep. Ken Calvert (R-CA)
View on Congress.gov ↗

Arguments For

  • The 'Political Cover' case: Supporting ALS research and expedited therapies is a universally popular, bipartisan win with zero political downside.
  • The 'Accountability' case: By mandating adverse event reporting and efficacy assessments for grant renewals, the bill protects patients and ensures taxpayer dollars are funding viable, safe therapies.

Likely Supporters

ALS AssociationI AM ALSMuscular Dystrophy AssociationRare disease patient advocacy groups

Arguments Against

  • The 'Bureaucratic Friction' case: Imposing new, strict reporting requirements on researchers and grant applicants could slow down the administrative process for developing urgent therapies.
  • The 'Agency Burden' case: Mandating the FDA to develop, publish, and report on a new 5-year action plan diverts limited agency resources and staff time away from actual drug approval processes.

Likely Opponents

Minimal organized opposition (potential quiet pushback from research institutions regarding reporting burdens)

📋 Key Provisions

  • Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act from 2026 to 2031.
  • Requires the Secretary to request and assess enrollment, safety, and efficacy data when reviewing grant renewals for investigational ALS drugs.
  • Mandates that entities seeking grants promptly report new, serious, and unexpected adverse events related to phase 3 trials to the grant-making institution.
  • Expands the definition of 'phase 3' clinical trials to include combined phase 2/3 trials that meet specific enrollment timeframes determined by the Secretary.
  • Directs the FDA Commissioner to publish a 5-year action plan for rare neurodegenerative diseases within 18 months, followed by a comprehensive progress report within 5 years.
search Verification Guide BETA expand_more

Don't trust AI? Don't worry, neither do I. Verify the claims yourself.

Claim Analysis Page 3, Line 10

Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through 2031.

Verify Text

"striking “2026” and inserting “2031”"

Claim Analysis Page 4, Line 14

Requires prompt reporting of new and serious adverse events for phase 3 trials.

Verify Text

"report any new and serious adverse events"

Claim Analysis Page 5, Line 18

Mandates the FDA to publish an action plan within 18 months of enactment.

Verify Text

"Not later than 18 months"